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6Imagine a world without cancer
Contributing to the fight against cancer means leaving a legacy and making a difference 
in the world. 
As a reputable professional, academic and scientific organization, the European Society 
for Medical Oncology (ESMO) is doing everything it can to keep oncologists at the leading 
edge of cancer care so that they can provide people living with cancer with the most 
effective treatments available, and the high-quality care they deserve. 
Great advances in basic science are being made today, and with your help new 
discoveries can be effectively translated into cancer therapies that enhance and 
prolong life.   That is why we are deeply grateful to Lombard Odier & Cie for producing this 
outstanding Donor’s Guide to Cancer.  The Guide will help you understand the many ways in 
which private donations can meaningfully contribute to prevent cancer, to relieve suffering, 
and to help save millions of lives. 
We join Lombard Odier & Cie in inviting you to partner with us and to ‘imagine a world wit-
hout cancer’.  As a private donor you have an important role to play in making this dream 
a reality. Your legacy will be gratefully remembered as a gift of comfort, and a promise of 
hope, to those in most need.
It is with deepest gratitude that I thank you for supporting the united efforts of the medical 
community to put an end to cancer, one of the major causes of suffering and premature 
death worldwide.
Martine Piccart, MD, Belgium 
ESMO President
Stronger, together
At ECL, the pan-European umbrella organization of national and regional cancer societies, 
we believe that the fight against cancer is one that can only be won by uniting the efforts of 
civil society, public authorities and donors. We also believe that fighting cancer does not only 
mean investing in research and treatments, but in a range of other intervention areas, which 
might be less obvious to donors but are equally important.
This guide helps donors identify other, less mainstream areas where their donations can 
make a real difference, such as prevention which is presently grossly underfunded. Indeed 
a third of all cancers is avoidable through making wiser lifestyle choices, hence making it a 
cost-effective long-term strategy for the control of cancer. The same is true for actions such 
as public policy, advocacy or coordination among actors, which are also areas that are in 
dire need of resources. 
The fight against cancer is not one that can be won without the support of private donors, 
and we hope this guide will help you navigate through the many options available and decide 
where you want to play a role.
Dr Wendy Yared, Director 
Association of European Cancer Leagues (ECL)
FOREWORD
Medical research has made vast progress in the fight against cancer, and every year brings 
discoveries that make us more knowledgeable and better able to battle the disease. Yet, 
cancer remains an invisible and silent threat for many of us. According to the World Health 
Organization (WHO), it has become the number one cause of death globally, taking more 
than seven million lives annually. 
Few of us have been spared the experience of watching a family member, loved one or friend 
suffer with the disease. This makes cancer both a very universal and an intensely personal 
experience – one that profoundly alters our priorities and outlook on life. It is also an expe-
rience that spurs many donors and volunteers to commit to fighting this plague, thereby 
joining the ranks of those who on a daily basis lead the battle to conquer cancer. 
Their remarkable work has borne fruit: never before has the prospect of defeating cancer 
been greater. The number of patients being cured is growing, and today a diagnosis of can-
cer is no longer synonymous with a death sentence. 
Many of the experts in this book agree that we are at the dawn of a “cancer revolution” that 
will transform the treatment of the disease from a standard approach to an entirely perso-
nalized one based on each patient’s unique genetic make-up. But this cancer revolution 
cannot take place without the mobilization of private donors. In many countries, they are the 
prime source of financing for the researchers and scientists who are constantly developing 
innovative and promising solutions to conquer the disease.
Your participation – whether in terms of time or of money – can make a real difference in the field. 
Many of the people I have discussed this subject with say they sometimes feel overwhelmed 
by the immensity of the challenge that cancer represents, or disoriented when presented 
with the wide array of areas in which they could make an impact. 
This guide is the result of our desire to provide them with answers to their questions. 
It is illustrated by Gabs’ drawings – often moving, always full of humor, and many excerpts 
from his book titled, “My Father Has Cancer”. Its aim is to guide you through the complex 
and multi-faceted field of cancer research. We hope you will find it a useful tool in your quest 
to identify those areas in which your participation makes the most sense to you, and in which 
your donation will make the greatest possible difference.
Anne-Marie de Weck 
Managing Partner, Lombard Odier & Cie
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Chapters in this guide are structured into several components, which appear with 
varying frequency from chapter to chapter:
A general introduction to each entry point, providing an overview of basic information  
of each issue.
SPOTLIGHT side-boxes provide more specific information about a particular aspect,  
challenge or watershed.
INTERVIEW WITH… are extracts of interviews we undertook with some of the world’s  
leading cancer experts who helped us draft this guide. Each highlights different points  
of view, stories and perspectives on the fight against cancer.
IN THE FIELD presents real examples of projects that are currently under way.  
These are not meant as recommendations to donors, but rather as eye-openers as to the 
multitude and heterogeneity of projects to which philanthropic support may be directed.
DONOR’S CORNER side-boxes provide more specific information about a particular aspect,  
challenge or watershed.
WHY A DONOR’S GUIDE?
At Lombard Odier, we are convinced that giving 
is not simply a matter of signing a check. It is the 
result of a complex endeavor that we call “the art of 
giving”. With over 200 years’ experience in philan-
thropy, we are convinced that, as industrialist and 
philanthropist Andrew Carnegie remarked: “It is 
more difficult to give money away intelligently than 
to earn it in the first place.” 
Why give? To whom? For what cause? What impact 
do you want to achieve? What are the chances of 
success, and what are the risks? Faced with a mul-
titude of issues, initiatives and solicitations, donors 
may rightly feel confused and disempowered. This 
is why Lombard Odier has established a philan-
thropy advisory service to accompany you in the 
challenging, yet fascinating, journey that is “the art 
of giving”.
This guide is an expression of this advisory service. 
It is addressed to individuals, families and private 
foundations who want to learn more about how they 
can use their wealth to serve noble causes. Its ambi-
tion is to provide answers to some of the questions 
that you should ask before starting your philanthro-
pic journey, and to provide you with the necessary 
tools for designing your own giving strategy accor-
ding to your values, resources and interests.
WHY CANCER?
We decided to focus our first donor’s guide on can-
cer. This is not because we consider this issue to be 
worthier than other causes, but because cancer is 
becoming a growing concern for society and among 
donors. This is hardly surprising: statistics show 
that one out of three people will develop a cancer at 
some point in their lives. It is therefore only natural 
that more and more individuals are willing to devote 
part of their giving to the fight against this disease. 
Many donors, however, shy away from cancer, 
because they consider this to be a far too complex 
area of intervention, or because they feel it is not a 
suitable territory for them. While cancer is indeed 
a challenging disease, the fight against cancer is 
multifaceted and there are many areas where your 
funding is critical. This is especially true in Europe, 
where cancer benefits from considerably less public 
funding than the United States, but also in emerging 
countries where the entire public health structure is 
deficient.
WHAT WILL YOU FIND IN THIS DOCUMENT?
This is not a scientific publication. Instead, it is in-
tended to be a practical, accessible and instructive 
tool. We do not set out to give an exhaustive account 
of all issues, but rather to provide the information 
and analysis required for a fuller understanding of 
the extent of the issue, the types of response offered, 
and the possible areas of intervention that you may 
want to consider supporting.
This guide begins with background information on 
the nature of cancer and on the burden that it re-
presents for individuals, families and humanity as 
a whole. It is then structured around eight “entry 
points” that we have identified in the fight against 
cancer. For each of these entry points, we give an 
overview of the nature of the challenges involved 
and of the promising solutions that are already in 
the making. Within each chapter, we decided to 
include the sometimes divergent opinions of a num-
ber of world-class experts as to what areas are cur-
rently underfunded or deserve your attention. We 
also included highlights of existing initiatives we 
found particularly innovative or inspiring. These 
are not meant as recommendations, but rather as 
eye-openers as to the multitude and heterogeneity 
of projects to which philanthropic support may be 
directed. 
WHERE DO WE GO FROM THERE?
We invite you to use the guide as an interactive 
map to take you easily to where, through a maze 
of potential opportunities, you may wish to pause 
and consider how best to engage in the fight against 
cancer. Progress is already underway in many areas, 
and recent breakthroughs give us added hope that 
cancer can be overcome. The current consensus in 
the cancer research community is that a new mo-
mentum is being created, and you may wish to add 
your weight to that momentum. We hope that this 
brochure will help you to decide where and how 
you could steer your philanthropic journey into the 
frightening, but fascinating, world of cancer. 
We are at your disposal, should you want to engage 
in conversation with us on this topic and learn more 
about specific initiatives.
TO THE READER 
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A BIRD’S EYE VIEW ON CANCER
WHAT IS CANCER?
Cancer is a disease in which a group of cells grows 
uncontrollably and acquires the ability to destroy 
adjacent tissues, to travel and invade other sites in 
the body, or to replace normal cells in essential body 
fluids, such as blood or lymph. Other names for can-
cer are malignant tumor, malignancy and neoplasm.
Cancer starts with a single cell in which several 
genes have undergone changes (mutations). These 
mutations allow the cell to make an unlimited 
number of copies of itself (proliferate), each copy 
carrying the same genetic mutations as the origi-
nal ‘parent’ cell. The mutations may occur spon-
taneously or as a result of external factors, such as 
exposure to ultraviolet radiation, environmental pol-
lutants, tobacco smoke, alcohol, certain infections, 
obesity and other cancer-producing (carcinogenic) 
factors (see Chapter 1, page 21). The result is a mass 
of endlessly-multiplying cancer cells that can grow 
and destroy normal tissues.
In the case of solid tumors (such as sarcomas and 
carcinomas), additional mutations may allow the 
cancer mass to develop into a virtually autonomous 
new organ with a life of its own. It may reprogram 
genes of the normal cells among which it resides, 
and recruit them to serve its own purposes. It creates 
its own blood supply and disguises itself to avoid 
being recognized and destroyed by the body’s im-
mune defenses.
In the late, or terminal, stages of the disease, cancer 
cells from the tumor may travel (metastasize) via the 
bloodstream or lymphatic system to different, and 
often distant, sites in the body, where they resume 
the cancerous process of unchecked growth and tis-
sue destruction, but with greatly increased aggres-
siveness. 
With liquid cancers (such as leukemia and lympho-
ma), the cancer cells multiply so much faster than 
standard blood or lymphatic cells that they “crowd 
out” and replace the normal cells, with potentially-
fatal consequences for the patient.
Although cancer derives from a single genetically 
“derailed” cell, it is not a single disease. Today, we 
know about 200 different types of cancer, each dif-
fering in genetic and molecular composition, in their 
location in the body, in the type of tissue they grow 
best in, and in many other respects.
HOW BIG A PROBLEM IS CANCER?
Every year, 13 million people in the world develop 
cancer, and there are currently about 25 million 
people living with cancer. Nearly two-thirds of these 
people will die from their disease. Studies have 
found that men have a nearly 50% chance of deve-
loping cancer in their lifetime and women about a 
30% chance.
It is true that new combinations of chemotherapy 
drugs over the past two decades have led to major 
increases in the survival rates of patients with cer-
tain cancers, such as breast, prostate and testicu-
lar cancers, and also certain leukemia in children. 
Advances in surgical and radiotherapy techniques 
permit more complete removal of solid tumors 
with minimal damage to the surrounding tissue, 
thereby improving survival. Yet despite these ad-
vances, cancer is still killing nearly 8 million 
people throughout the world every year, making it 
the second leading cause of death after cardiovas-
cular diseases. Today, cancer accounts for one out 
of eight deaths worldwide, more than HIV/AIDS, 
tuberculosis and malaria combined.
What is more, cancer is on the rise and is likely to 
become the world’s no. 1 killer in the near future. 
Assuming no change in risk factors, by 2030: 
• The number of new cases annually will have es-
calated from the current 13 million to 26 million.
• The number of people dying from cancer an-
nually will have soared from nearly 8 million 
today to 17 million. 
• Developing countries, where most of the in-
crease in cancer cases and deaths will take 
place, will account for 70% of new can-
cer cases occurring in the world vs. 50% at 
present.
“A malignant tumor is not just 
a lump of cancer cells  
as is often thought. It is an organ 
and functions just like one, 
with blood vessels, 
immune cells and 
other tissue cells recruited  
to support it and
provide its needs.”  
Douglas Hanahan
Director, Swiss Institute  
for Experimental Cancer Research
DIFFERENT CANCERS, DIFFERENT INCIDENCES
In 2010, the cancers with the most new cases worldwide were lung (12.8% of new cases), 
breast (10.9%), colorectal (9.8%), stomach (7.8%) and prostate (7.1%). However, the most 
deadly cancer, i.e. carrying the highest risk of mortality (case fatality rate) and the lowest 
chance of survival, is cancer of the pancreas, followed by cancers of the liver, esophagus, 
brain, and lung.  
Cancer incidence, however, 
differs strongly depending on 
gender, income, ethnicity and 
other factors.
For example, the most  
common cancers among women 
are breast and cervical cancer, 
while the most common cancers 
among men are lung and pros-
tate cancer. 
The predominance of different 
types of cancer is also different 
between richer and poorer 
countries. While cancers of the 
lung, breast and stomach rank highly across all country income groups, for some other  
cancer sites, the pattern varied. For example, cervical cancer was responsible for 12% 
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The main reason why developing countries will bear 
the brunt of what has been called “the cancer tsuna-
mi” is that these societies are catching up with many 
of the cancer-prone trends traditionally associated 
with the more developed world. 
Aging, for example, is the strongest risk factor for 
cancer. Developing countries are also increasingly 
adopting a cancer-prone lifestyle such as cigarette 
smoking, lack of physical exercise, nutritional ha-
bits that foster obesity, excessive exposure to sun-
light and other risky behaviors. 
THE ECONOMIC BURDEN OF CANCER
Of all causes of death worldwide, cancer has the 
greatest economic impact from premature death 
and disability. Its global economic toll has been 
estimated to be 20% higher than that of any other 
major disease.
The 13 million new cases of cancer in 2010 were 
estimated to cost a total of US $290 billion, accor-
ding to recent analysis. Medical costs accounted for 
just over half of the total, with non-medical costs 
and income losses accounting for the rest (Figure 1).
Figure 1 shows the estimated costs for the four most 
costly cancers. With the likely twofold upswing in 
the world’s cancer burden over the next 20 years, 
total annual costs of new cancer cases are also ex-
pected to double, reaching US $458 billion by 2030. 
According to another study published by the Ame-
rican Cancer Society, the global economic impact 
of premature death and disability from cancer 
worldwide was $895 billion in 2008. This figure re-
presents 1.5% of the world gross domestic product.
WHO IS RESPONSIBLE FOR  
THE CANCER RESEARCH BILL?
A survey conducted by the European Cancer Re-
search Managers Forum (ECRM) has come up with 
an estimated annual total of US $14 billion being 
spent worldwide on cancer research alone. Europe 
and the US are estimated to account for 60% of glo-
bal funding, although the actual amount spent per 
capita by the US is about five times greater than the 
European per capita average. The funding patterns 
between the two are very different: 96% of total US 
funding for cancer research comes from the govern-
ment, mainly through the US National Cancer Insti-
tute, leaving only 4% for charities and foundations. 
By contrast, government agencies in Europe account 
for only 53% of cancer research funding, leaving 
47% for charities and foundations (Figure 2). Phi-
lanthropy, however, is a complex phenomenon with 
different attributes and giving patterns almost on 
a country-by-country basis, as shown (Figure 3). 
Nevertheless, it is clear that European foundations 
and donors are playing a relatively greater role in the 
funding of cancer research than their counterparts in 
the US, yet it remains a relatively poorly recognized 
source of income.
STEP-BY-STEP TO A CANCER-FREE WORLD
Efforts are being made across a broad range of acti-
vities to reduce the number of people getting cancer, 
living with cancer, and dying from cancer. Efforts 
are also being made to improve the quality of life of 
cancer patients and their families, and to reduce the 
inequalities associated to this disease. 
The objectives of these efforts are realistic and achie-
vable. And to a certain extent, in certain places, they 
are being achieved, slowly, but surely. In other places 
though, particularly where resources are lacking, pro-
gress is at a standstill or moving too slowly to keep up 
with the ever-faster pace at which the cancer burden 
is growing.
If you are considering engaging in the fight against 
cancer, the task of choosing what actions to support 
might seem daunting. To make it easier for you, we 
have identified eight different, yet interdependent 
and mutually reinforcing, “entry points” in the fight 
against cancer. We hope that this framework will help 
you to see more clearly the role you might wish to play, 
“A massive ‘pandemic’ of deaths 
and disease from cancer is expected 
over the next two decades.  
It will be a real tsunami. Why?  
Because the developing world  
is facing the same risk factors  
that put cancer on center stage 
in the richer countries — an  
aging population, increasing use  
of tobacco and alcohol, and obesity 
from lack of physical activity.”  
Andreas Ullrich
Director, WHO Cancer Department
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Income losses
Non-medical costs
Estimated number of new cancer cases (2010)
(in thousands)
Medical costs
1.  Estimated costs of new cancer cases 
    by cancer site and cost component, 2010 
     (in billions of 2010 US $) 
  




























Source: The Global Economic Burden of Non-communicable Diseases. 
A report by the World Economic Forum and the Harvard School of Public Health. September 2011
2.  Cancer research: funding by source
























Source: Full report at www.ecrmforum.org & Eckhouse S, 
Sullivan R. A Survey of Public Funding of Cancer Research in the European Union PLoS Medicine 3 (7), e267.

























































3.  Direct spend in Europe by Country, shown as Government against Charity funding streams
(in million €)
16
A BIRD’S EYE VIEW ON CANCER
with regard to one or more areas of activity. Although 
there is no right or wrong area to target for funding, 
and each has potential for promising advances, some 
may be more or less suitable for private donors. Also, 
it is natural that each of these entry points resonates 
differently with each one of you, according to your va-
lues, ambitions, experiences and preferences. Finally, 
you may decide to place your support in one specific 
area or niche, or to diversify your action over several 
areas. The following chapters of this guide present 
each of these eight entry points in detail, 
with specific focus on those aspects that hold 
great promises and could greatly benefit from 
your support. 
“Progress in fighting cancer  
will happen stepwise,  
not all of a sudden.  
You will see progress  
on a subtype of lung cancer or  
a subtype of breast cancer  
and a subtype of colorectal cancer 
perhaps every other year  
or every three or four years.  
But it will be a long stepwise  
battle to get more and more  
of the different diseases  
within cancer under control.”  
Alexander Eggermont
Director, Institut Gustave Roussy


































“The drugs discovered  
by researchers gave me  
a second chance.  
They are the reason  
I can wake up every morning.” 











For most of us, cancer is an unavoidable threat — a 
sword of Damocles ready to fall at the slightest whi-
mof fate. Yet according to experts, cancer is not una-
voidable. In fact, some researchers claim that it may 
be the most avoidable of all chronic diseases. 
The genetic instability that causes cancer to initiate 
and grow is inherited only in a small percentage 
of the population, and cancer incidence is mostly a re-
sult of a combination of environmental factors,which 
include lifestyle and infections.
LIFESTYLE AND CHOICES
Over the past decades, epidemiological research 
has identified factors that increase the risk of deve-
loping cancer. In about 50% of cancer cases, these 
factors are linked to lifestyle or personal choices, 
so in principle about half of cancers could be pre-
vented by avoiding these lifestyle risk factors. 
These avoidable risk factors include:
 
TOBACCO USE, the most devastating risk factor, 
is estimated to account for 22% of all cancer deaths 
worldwide. Multiple studies have shown that male 
smokers are about 23 times more likely to develop 
lung cancer than non-smokers. Smoking is accoun-
table for 90% of lung cancers incidence and over 
one-fifth of all cancer deaths. Other than lung can-
cer, tobacco is associated with least a dozen other 
types of cancer, including cancer of the throat, 
mouth, nasal cavity, esophagus, stomach, pancreas, 
kidney and bladder.
 
ALCOHOL ABUSE is associated with cancers 
of the mouth (oral cavity), liver, pharynx, larynx, 
esophagus, breast and colorectum. According to a 
recent study, alcohol is accountable for 44% of up-
per aerodigestive tract cancers, 33% of liver cancers 
and 17% of colorectal cancers in men. 
INSUFFICIENT PHYSICAL ACTIVITY, com-
bined with poor nutrition and excessive bodyweight, 
are also very high risk factors and are particularly 
linked to cancers of the breast, colorectal, stomach 
and esophagus. In the United States, evidence sug-
gests that about one-third of cancer deaths in 2012 
will be related to obesity, physical inactivity and 
unhealthy diets.
INDOOR TANNING and excessive exposure of 
skin to sunlight (ultraviolet radiation) cause skin 
melanoma, to which fair-skinned, blue-eyed people 
of Celtic origin are particularly prone. Some stu-
dies show that about 65% to 90% of melanomas 
are caused by exposure to ultraviolet light, and that 
many of the 2 million plus skin cancers diagnosed 
annually could be prevented.
ENVIRONMENTAL AND OCCUPATIONAL 
EXPOSURE, including urban air pollution, smoke 
from indoor use of solid fuels, asbestos, radon, pes-
ticides and other toxins present in consumer goods 
(including building materials, food and drink), are 
estimated to account for 2 to 4% of cancer deaths.
CANCER-CAUSING INFECTIONS 
A number of infectious organisms, such as the hepa-
titis B virus (HBV), human papillomavirus (HPV), 
human immunodeficiency virus (HIV), Helicobac-
ter pylori, and others, have now been identified as 
causes of cancer. Together, they account for 18% 
of cancer cases worldwide and up to 26% cases in 
developing countries. In fact, many of the most com-
mon cancers in developing countries, such as can-
cers of the liver, stomach and cervix, are caused by 
infections. To date, vaccines are available for only 
two cancers caused by viral infections — cervical 
cancer caused by HPV and liver cancer caused by 
hepatitis B — but these two cancers already account 
for 10% of cancer cases worldwide.
PREVENTING CANCER ALTOGETHER
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“Tobacco is responsible for more 
than 15 types of cancer. It is our chief 
weapon against cancer, quantitatively 
speaking. By simply stopping tobacco 
use, we would prevent almost two 
million cancer deaths a year.”  
Andreas Ullrich 
Director, WHO Cancer Department
1
HORMONAL RISKS
Hormones play a complex role in determining the 
development of cancer by promoting cell proli-
feration, and are critical factors in cancers of the 
breast, uterus, ovaries, prostate, testes, thyroid and 
bone. The high-risk behavior patterns associated 
with these cancers include:
• Late pregnancies, lack of children, no 
breastfeeding, or hormone replacement the-
rapy (HRT) for menopausal problems.
• Use of oral contraception is shown to slightly 
increase the risk of cancer of the breast and 
cervix, but reduces the risk of cancer of the 
ovaries and uterus.
• On the other hand, removing the uterus (hys-
terectomy) or tying the fallopian tubes (tubal 
ligation) will drastically reduce the risk of 
cancer of the ovaries. 
Although experts have recognized these risks for 
years, they are still not sufficiently understood by 
the wider public. 
PREVENTING CANCER ALTOGETHER
22
Anne, a 36 year-old, explains: 
“I would have had a lot of lifestyle changes had I 
known of the risks beforehand: I took the pill for 14 
years, and never had any kids, so that’s a double-
whammy. I also would have cut back on drinking 
and paid more attention to my weight and diet. If 
there had been more emphasis on breast cancer in 
health classes in school, I know it would have chan-






Some cancer risks do not lend themselves to individual control or choice. All biological  
risk factors are, by definition, unavoidable, and include age, gender, ethnic origin, skin  
complexion and hereditary traits. Other risks, such as certain infections, are currently  
unavoidable, although this might change in the future. 
Age is clearly the most important unavoidable risk factor: in the United States, for example, 
about 77% of all cancers are diagnosed in people aged 55 and older. 
Some reproductive risk factors, such as onset of menstrual bleeding (menarche) at an early 
age, onset of menopause at a late age and infertility, are all unavoidable risk factors for 
cancer of the uterus (endometrium).
As for hereditary transmission of cancer, it is important to stress that what is inherited is a 
predisposition to cancer, and not cancer per se. Parents can pass on to their offspring genes 
with potentially cancer-leading mutations: people with these mutations have a ‘head start’ 
on the cancerous process, as a mutation that can contribute to cancer is already present in 
every one of their cells. However, only about 5% to 10% of all cancers are the direct result 
of inherited gene mutations. 
There are three cancer-causing infectious organisms for which no vaccine exists: 
-  The bacterium Helicobacter pylori causes an estimated 490,000 cases of stomach 
cancer every year, accounting for more than 5% of cancer cases worldwide.
-  HIV, the AIDS virus, indirectly causes cancer by lowering overall immunity. Kaposi  
sarcoma, a cancer found in up to 50% of AIDS patients, is caused by a virus that 
takes advantage of these patients’ deficient immunity. 
-  Hepatitis C virus causes an estimated 70,000 cases of liver cancer.
THE PROBLEM
Cervical cancer is the second most-common cancer amongst women worldwide.Every year, 
530,000 women are diagnosed, and 275,000 women die from this cancer, almost 90% of whom 
are in developing countries. This is all the more disturbing given that cervical cancer is both 
preventable through vaccines and easily detectable and curable if screened early enough. In 
fact, cervical cancer is the result of lesions caused by the Human Papillomavirus (HPV), the 
most common sexually transmitted infection. It is a slow maturing cancer, and usually takes 
more than ten years for the infected lesion to become a cancer. However, in poorer countries 
with inadequate resources, most cervical cancers are diagnosed in women around the age of 45, 
by which time the cancer is too advanced for treatment. 
In Latin America, cervical cancer is the leading cause of cancer deaths in women, killing 31,700 
women every year in the region. More specifically, El Salvador has the second highest number 
of cervical cases (over 1,100) and deaths (560) after Guatemala, although a national guideline 
is in place and the two vaccines against HPV are legally registered.
THE IDEA
A four-year pilot project is being conducted in El Salvador as a multi-partnership initiative 
involving the Union for International Cancer Control (UICC), the Ministry of Health and a 
local civil society organization (ASAPRECAN). The project is also being run in conjunction 
with the World Health Organization (WHO) activities in the region. In each department, the 
project plans to introduce mass HPV vaccination, made available in schools, churches and 
mobile clinics. It will also provide low-cost and on-the-spot screening, as well as treatment 
(a solidarity fund will cover the costs for those women who need it). Throughout the project, 
awareness-raising campaigns will be run through community centers and via local media 
to encourage families to vaccinate their daughters, and encourage women to be screened. 
Lastly, the project will work with the International Agency for Research on Cancer (IARC) 
and the El Salvador Health Ministry to improve the country’s cancer registry.
THE IMPACT 
In its four years of existence, the project will screen 10,000 women aged between 30-40, 
and vaccinate 52,700 girls (85% coverage of girls aged between 10-14) in the departments 
of Sonsonate, Cuscatlán and San Vicente. The project will also target 120,000 men and wo-
men with direct community education activities. Working hand-in hand with the Ministry of 
Health, it also supports the preparation and implementation of an improved national strategy 
to tackle cervical cancer.
The long-term objective of this pilot project is to show the significant socio-economic impact of 
the use of early detection, treatment and preventive vaccination to reduce the number of women 
with cervical cancer. The ultimate aim is for this project to become a case for the implemen-
tation of cervical cancer vaccine and screening throughout the rest of the country and in other 




Preventing cervical cancer in El Salvador
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ADVOCACY & PUBLIC POLICY 
All too often, laboratory discoveries take years to enter the public domain and inform policy 
making. Raising awareness about the consequences of certain risk factors and changing policies 
to reflect those risks is a challenging, but necessary and highly impactful, area of intervention. 
As a private donor, you can help fund the publication of position papers that will help to 
shape public policy on issues such as healthy diets in schools and cafeterias. You could also 
support awareness-raising campaigns that highlight the benefits of physical activity, or help 
finance lobbying initiatives to regulate the use of certain high-risk substances. Many 
organizations are already active in these fields, but need more money to scale up and replicate 
their initiatives. 
RESEARCHING RISK AND ANTI-CANCER FACTORS
Much more research is needed to understand how certain substances play a determining role in 
causing or preventing tumor development. Identifying these factors will be key in the fight against 
cancer. Studies are currently underway into a wide range of risk factors, including pesticides, 
electromagnetic waves and certain chemicals used in the food industry (e.g. aspartame). At the 
same time, other research seeks to understand whether, and how, certain substances (including 
green tea, soy and certain spices) can reduce the incidence of cancer. Private donations to research 
projects in these fields can help us to understand how the number of people getting cancer can 
be reduced.
CHEMOPREVENTION DRUGS AND VACCINES
In recent years, there has been a lot of progress made in the field of chemoprevention drugs and vac-
cines: approximately 150 clinical trials are currently underway to identify drugs that can reduce the 
incidence of cancer in people at risk (e.g. due to hereditary predisposition, exposure to occupational 
risks). Another, related, area is that of vaccines to treat cancer-causing viruses, because 
funding is needed not only for research into new vaccines (e.g. for Helicobacter pylori and 
Hepatitis C), but also for improving access to existing vaccines. This is especially important in 
developing countries where deaths from preventable liver and cervical cancers are increasing all 
the time. In most instances, this aspect is an underfunded area of engagement in which private 




Primary prevention provides an ideal opportunity for private donors: less than 5% of all 
funding is dedicated to primary prevention and identifying environmental links to the 
disease, because this area is of little interest to the pharmaceutical industry, and is still 
poorly supported by the public authorities. What’s more, cancer prevention could have 
wider positive repercussions, since many risk factors for cancer are shared with other 
common conditions, such as vascular disease and diabetes. 
There are many actions you can take to drastically reduce the number of people who 
develop cancer (thereby significantly reducing the human and financial cost of this 
disease). These actions may take many different forms in order to tackle the various 
aspects of this challenge.

“Basic research needs donations  
to continue developing efficient  
personalized therapy.” 











DETECTING CANCER AS EARLY AS POSSIBLE
Today, it is widely acknowledged that the earlier 
the diagnosis of cancer is established, the more 
likely the chances of successful treatment will be. 
In fact, early detection is thought by many experts 
to be the most promising and most feasible means 
for reducing cancer deaths. The question is: how 
early is early in relation to the progression of can-
cer? Many cancers take decades to digress from 
a single mutant cell to a full-blown metastatic 
disease. 
This time lag offers a large window of opportunity 
in which to detect malignant tumors at an early 
enough stage for a cancer to be still curable. For 
example, before developing colorectal cancer, one 
of the most common cancers among men, patients 
typically develop a benign growth called a polyp, 
which will take between 5 to 10 years to become 
a tumor. If there were a simple blood test to iden-
tify polyps (see ‘Spotlight: Biomarkers’) and have 
“We need much more research on 
better ways of preventing cancer and 
research that focuses on the earliest 
stages of cancer progression.  
We desperately need to find marker  
molecules in the blood of people who  
are not yet patients. We need molecules 
that will tell us that this or that person  
has got cells that are likely to become a 
breast cancer. We need a blood or stool 
test to detect at the very earliest stages 
a polyp that could turn into a malignant 
tumor in the intestine.”    
Alexander Eggermont 
Director General, Institut Gustave Roussy
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them removed through a simple colonoscopy, 
some 600,000 fewer people would die from this 
sort of tumor every year.
Some research suggests that at least half of all can-
cer deaths could be prevented if detected earlier. 
Regular check-ups and screenings by healthcare 
professionals can indeed result in the detection and 
removal of precancerous growths (for example for 
cancers of the cervix, colon and rectum), as well as 
diagnosis of cancers at an early stage, when they 
are most treatable. Screening can be done using a 
number of different techniques and examinations. 
These include:
PHYSICAL EXAMINATION AND PATIENT 
HISTORY: Physical examinations should be made 
regularly either with your general practitioner or in 
a hospital. Usually performed by general practitio-
ners, these consist of examining the body to check 
for general signs of health, and to look for lumps 
or anything else that seems unusual. An analysis of 
the patient’s health habits, past illnesses and family 
history should also be conducted.
LABORATORY TESTS: If there is a reason to 
suspect cancer, doctors may order certain can-
cer laboratory tests or decide on a biopsy. These 
procedures test samples of tissue, blood, urine or 
other substances in the body to check for cancer 
cells or specific markers (see Spotlight: Biomar-
kers). These tests are very commonplace, and may 
include PSA (Prostate-Specific Antigen) blood 
tests for prostate cancer and ‘Pap smears’ (Papani-
colaou tests) for cervical cancer.
IMAGING PROCEDURES: An imaging test is 
a technique used to see what is going on inside the 
body. Imaging procedures send forms of energy (x-
rays, sound waves, radioactive particles or magne-
tic fields) through the body. The changes in energy 
patterns made by body tissues create an image or 
picture, which can help to identify abnormal tis-
sues, such as cancer. These tests include procedures 
such as MRIs, ultrasound or mammograms. Ima-
ging tests are somewhat different from endoscopies 
(such as a colonoscopy or bronchoscopy), which 
consists of inserting a flexible, lighted tube with a 
lens or a video camera inside the body to get a bet-
ter view of any potentially-damaged organs.
GENETIC TESTING: Genetic testing (also cal-
led DNA-based testing) is one of the newest and 
most sophisticated techniques used to determine 
the likelihood of a person developing cancer. 
These tests analyze genes, chromosomes or pro-
teins to help predict the risk of disease and iden-
tify carriers. More than 1,000 genetic tests are 
available for many different diseases, including 
breast, ovarian, colon, thyroid and other cancers. 
Although techniques and procedures have pro-
gressed greatly in recent decades, screening still 
has shortcomings:
• Firstly, only certain cancers can be diagnosed 








In a recent film version of Alice in Wonderland, the Queen of Hearts inspects a line  
of frog footmen to determine which frog ate her tarts. One footman has a bit of jam 
in the corner of his mouth that gives him away. That jam is a biomarker, a physical 
clue about an otherwise invisible problem or process. 
Much hope in the field of early detection is being placed on so-called “biomarkers”:  
a biomarker is generally a protein molecule that can be detected in a blood test, and may 
denote the presence of cancer in a person’s body.
Amongst the well-known biomarkers of cancer, high levels of prostate-specific antigen (PSA), a 
molecule found in the blood of all men, may indicate a risk of prostate cancer. The Philadelphia 
chromosome, another biomarker, is found in 95% of people with a certain form of leukemia. 
Today, there are about a dozen biomarkers used to detect cancer, and many more are currently 
being researched, as well as ways to detect them more efficiently, effectively and at lower 
costs.
Some biomarkers are also being used for treatment. A biomarker drug will kill the specific 
unique cancer of the patient without damaging normal cells, as traditional chemotherapy does 
(see Chapter 6, page 61). 
Measuring changes in the concentration of a biomarker in a patient’s blood can also indicate 
whether treatment is likely to work or is working effectively, how aggressive the patient’s tumor 
is, what the patient’s prognosis is, and whether, in a cancer survivor, the cancer is recurring. 
However, biomarkers do have a downside. Not every cancer produces a biomarker, and not 
every biomarker is specific to a given cancer. However, they can be used by doctors to flag-up 
issues for further diagnosis.
cers of the breast, colon, rectum, cervix, pros-
tate, oral cavity and skin. Furthermore, early 
detection does not always improve the chances 
of successful treatment or help the person to 
live longer.
• Secondly, false test results are possible: scree-
ning results can sometimes appear abnormal, 
even though there is no cancer present, or ne-
gative, even where tumors are present.
• Lastly, diagnostic testing procedures require fi-
nancial, technological and logistical resources 
that are often beyond the means of developing 
countries and are seen as of less importance in 
richer ones.
Despite all these drawbacks, screening remains 
one of the best resources we have to fight can-
cer, and it should be used more consistently, even 
where patients are not at risk. For example, Lau-
ren, a 35-year-old mother with three kids under 
the age of 7 and no family history of cancer, had 
never thought of breast cancer. However, when her 
husband was transferred abroad, her gynecologist 
suggested that she should have a mammogram be-
fore they went abroad. “That mammogram saved 
my life. My priority today is about bringing awa-
reness to a disease that is sometimes ignored by 
young women.”
DETECTING CANCER AS EARLY AS POSSIBLE
THE PROBLEM
Between 5-10% of cancers are due to genetically-inherited predispositions. People with such 
predispositions should undergo special examinations and have regular check-ups to enable 
early detection. However, identifying these patients is not always easy, and this is why the 
development of a simple and inexpensive marker to identify those most at risk of developing 
the major types of cancer would be very useful in terms of public health.
THE IDEA
A team from the Institut Curie, led by Dr Mounira Amor-Guéret, is working on a rare genetic 
disease called Bloom syndrome (BS), which combines specific abnormalities of the chromo-
somes with a high risk of developing cancer. The team recently demonstrated that the cells of 
these patients presented very low levels of an enzyme called cytidine deaminase (CDA). The 
results of their studies indicated that CDA deficiency contributed to Bloom syndrone. More 
interestingly, results also strongly suggested that CDA deficiency in individuals not affected 
by Bloom syndrome predisposed them to cancer. CDA is very easy to diagnose by a traditio-
nal blood test, so the project aimed to determine whether CDA could become a cost-effective 
and efficient marker for determining the risk of cancer. Tests were conducted on over 200 
patients, and research is now underway to understand these results and undertake new trials.
THE IMPACT 
The results of this research could lead to the first identification of an alteration of an enzyme 
(which may have a genetic, as well as environmental, origin), which could be used as a 
marker for cancer predisposition. One of the most important benefits of this research would 
be the identification of an extremely simple and inexpensive detection tool and the establish-
ment of procedures to monitor individuals and families with abnormal CDA levels. 
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A biomarker to cancer predisposition
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RAISING AWARENESS 
Reinforcing the importance of early detection remains critical. Early detection should be performed 
among the general population and specific high-risk target groups. Advertising campaigns pro-
moting Pap tests in women or regular PSA tests among men are relatively cost-effective measures 
that you could support and that could help boost early detection and drastically reduce the 
cancer burden. 
ADVOCACY AND PUBLIC POLICY
Legislation and public health systems are lagging behind in terms of institutionalizing medical 
findings: for example, in most European countries, mammographies are performed on women 
aged over 50, although about 20% of breast cancers develop in younger women. For a donor, 
this could mean supporting working groups and white papers that would help to introduce better 
cancer screening measures in national health plans, or advocating the adoption of innovative and 
cost-effective tests and measures. 
TRAINING TO DETECT
Detection should be more widely taught, both to medical staff and the wider public. For example, 
you could support training programs to teach simple and cost-effective measures, like breast 
self-palpation or skin self-examination in schools and in the workplace. More funds are also 
needed to train all medical staff, including nurses and general practitioners, to detect early signs 
of cancer, and to perform routine testing (see In the field, Chapter 8, for some innovative training 
programs targeted at visually impaired women).
IMPROVED ACCESS
Although some sophisticated and highly reliable screening techniques do exist, access is not easily 
available to everyone. This is especially true in developing countries, but also in Europe and North 
America amongst disadvantaged communities and suburban and rural communities. You could 
change this by supporting initiatives that help reduce inequality in early screening, such as helping 
to fund imaging machinery or low-cost, low-technology blood tests that could help save thousands 
of lives.
NEW AND IMPROVED TECHNIQUES
Existing screening and detection techniques could be further improved and developed. This is 
particularly true in the case of biomarkers, many of which are currently under development, and 
imaging techniques, which are becoming more and more effective, but are still very expensive. 
In this area, as a private donor it is important to concentrate on specific research projects or needs 
(for example, lab equipment or fellowships) that are not already adequately covered by public 
funding or pharmaceutical companies.
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DONOR’S CORNER
Screening and early prevention are priority areas in the fight against cancer, and 
although much has been done in recent decades, challenges still remain. Prevention 
research must assume a higher profile and greater importance in the broad cancer 
research strategy and in those cancer plans currently being developed. Much of this 
is already covered by governmental programs and by pharmaceutical companies that 
can develop highly profitable tests. However, there is still room for donors in a number 
of areas.
DETECTING CANCER AS EARLY AS POSSIBLE

“Cancer research is the future. 
Encouraging donations  

















Stem cells, found in embryonic and some adult tissues, have the potential to develop into  
cells of many different organs and tissues. Such cells have recently been found in malignant 
tumors. These so-called cancer stem cells are like “super cancer cells” with the ability to 
proliferate infinitely and resist both chemotherapy and radiation. 
 
Researchers now believe that many human cancers develop from these stem cells, and  
that therapies often founder because they fail to kill the cancer stem cells. 
The ever-increasing research efforts into the field of stem cells carry a promise to provide  
missing pieces of the puzzle of discovering and targeting the Achilles heel of cancer cells, 
which would have a major impact on the development of innovative strategies to conquer 
cancer.
Basic research (also referred to as pure or funda-
mental research) aims to increase understanding 
of the fundamental principles underlying cancer 
growth, as well as how it spreads throughout the 
body, killing healthy cells.  Although this research 
is not intended to deliver immediate benefits or so-
lutions, in the long term, it will represent the foun-
dations for applied solutions, be they in prevention, 
screening or treatment. Many of those touched by 
cancer understand this challenge, as explains Nancy 
Bouchard, whose son fought cancer, non-Hodg-
kin’s lymphoma (NHL) Type B: “Only research 
will make it possible to identify the causes of this 
disease and take the measures required to prevent 
it. My son was cured thanks to the efforts and re-
sources invested in cancer research over the course 
of many years. Every day, scientific research gives 
us a better understanding of the complexity of this 
disease. Better understanding means adopting in-
creasingly effective methods, better tools, diagnos-
tics and treatments to beat it.”
According to many, cancer-related basic research 
is burgeoning: some speak of “a scientific revolu-
tion”, others of “a new era of cancer medicine”, 
yet others speak of being “at a defining moment in 
our ability to conquer cancer”. Progress is certainly 
being made, largely thanks to new breakthroughs 
and technologies developed over the past decade. 
For example, probing the genetics of cancer cells, 
which has become a cornerstone of current cancer 
research, owes much to the Human Genome Pro-
ject, which was completed in 2003 after identifying 
all the 20,000 to 25,000 genes in human DNA. 
Moreover, technologies such as nanotechnology 
have allowed a leap forward, allowing researchers 
to explore and manipulate cancer-related molecules 
that are important during the very earliest stages of 
cancer progression.
Basic research currently revolves around three 
main approaches. While being very distinc-
tive, these three areas are complementary, and 
are all seeing huge strides forwards that justify 
the current optimism that pervades the cancer com-
munity today. 
GENOMICS: Genomics involves the study of 
DNA and the mapping of the different genes that 
make up the genome (the complete set of genetic 
material of an individual). It is one of the most pro-
mising fields and frontiers to understanding cancer. 
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“We have at hand the methods  
to identify essentially all of 
 the genomic changes in a cell and 
 to use that knowledge to rework  
the landscape of cancer research.  
This knowledge gives us a 
 crucial opportunity to accelerate 
 research into the study of cancer  
and its treatment.”   
Harold Varmus
Director, National Cancer Institute (USA)
More specifically, genomics allows the tracing of 
a “blue print” of each tumor for improved unders-
tanding in how to fight it. In fact, each cancer has 
a genome sequence, or blueprint, that is specific to 
it, irrespective of its location (lung, breast, etc.). If 
we identify subclasses of cancers according to their 
genome sequence, rather than their location, we 
can focus on treating and preventing these cancers 
accordingly. 
UNRAVELLING COMPLEXITY
EPIGENETICS: We have learned that genes alone 
are not enough to explain how cancer arises. It is 
becoming clear that the chemical “packaging” on 
which genes sit can also determine how cells func-
tion and potentially evolve into cancer cells. This 
area of research, known as epigenetics, is a recent 
addition to the body of knowledge on cancer, and is 
becoming an increasingly important area of cancer 
research. According to the International Agency for 
Research on Cancer (IARC), epigenetics is “one of 
the most rapidly expanding fields of modern bio-
logy, with enormous implications on our thinking 
and understanding of biological phenomena and 
diseases, especially cancer”.
PROTEOMICS: This is the study of proteins, and 
more specifically proteins typically associated to 
certain tumors, known as biomarkers, that can be 
useful to diagnose cancer. Proteomics enables the 
identification and classification of cancers, not 
according to their genetic modification, but accor-
ding to the way they interact with the system and 
evolve. This is because while the genes are the 
“ingredients” of the cell and the epigenetics are the 
“recipe”, the proteins encoded by the genes are ulti-











DOUGLAS HANAHAN,  DIRECTOR OF THE SWISS INSTITUTE FOR EXPERIMENTAL  
CANCER RESEARCH, AND PROFESSOR OF MOLECULAR  
ONCOLOGY IN THE SCHOOL OF LIFE SCIENCES AT 
THE SWISS FEDERAL INSTITUTE OF TECHNOLOGY, LAUSANNE.
The mood today in the cancer research community seems upbeat. Do you share this 
optimism? 
There are certainly developments to be optimistic about. With the new technologies that have become 
available to us in the past five to ten years, we can now look inside a cancer. What we’re seeing is  
really exciting. We are seeing how genetic mutations can turn normal cells into cancer cells by  
reprogramming the entire functioning of normal cells. We are gradually gaining an understanding of 
how this reprogramming is achieved, and I’m sure we’re on our way to using that understanding to fight 
cancers more effectively. So, yes, I am very optimistic, but also realistic. We’re still far from the end of 
the road, but we’re on our way.
What important questions does basic research still have to answer?
One exciting frontier of research that calls urgently for an answer is why tumors adapt to, and resist, 
treatment. Very often when chemotherapy or radiotherapy is administered, the cancer recedes or seems 
to disappear, but then after a time returns with a vengeance. It has in some way adapted and become 
resistant to the treatment. A growing number of research labs are trying to find out just why and how 
cancers do this. 
Is this research producing any findings that could have a direct impact on the current 
treatment of cancer patients? 
We do have interesting leads. You see, the chemotherapy and radiotherapy that are used to kill cancer 
have up until now been targeted just at cancer cells. But we have found that a malignant tumor lodged 
in a tissue can recruit a variety of normal cells from the adjacent tissue to produce a supporting cellular 
framework that we call a tumor “microenvironment”. The recruited cells join up, as it were, with the 
cancer cells to help the tumor grow and invade other tissues. We are finding that the microenvironment 
contains many different types of cell – blood vessel cells, immune cells, and many other types of cell. 
We are now trying to understand how these cells are recruited by the tumor, what they are doing to help 
the tumor, and what signals they exchange with each other and with the cancer cells. It could be that 
this microenvironment of recruited cells plays a part in the adaptive resistance of cancers to toxic drugs 
and radiation. We did attempt some years ago to try and destroy the network of blood vessels that bring 
nourishment to a tumor, but that approach only had a transient effect on the tumor. If our research  
shows us that it’s the whole supporting microenvironment that we need to attack, that would be a  
real breakthrough and would force us to change or expand the treatment targets we’ve been using up 
until now.





The causes of childhood cancers are still largely unknown. Typically, factors that trigger cancer 
in children usually differ from those that cause cancer in adults, such as smoking or exposure 
to environmental toxins. In most cases, childhood cancers appear to arise from mutations (or 
changes) in the genes of growing cells. Some of these gene mutations may be inherited, while 
others occur randomly and unpredictably, and there is no effective way to prevent them. Some-
times, a doctor might spot early symptoms of cancer at regular check-ups. However, some of 
these symptoms are quite generic (e.g. fever, swollen glands, anemia) and can be associated 
with many other more common conditions. Because of this, it is important to learn more about 
childhood cancer and how genes are involved in their development. 
THE IDEA
In 2006, a team led by Professor Nazneen Rahman of the Institute of Cancer Research set 
up the FACT Study (Factors Associated with Childhood Tumors): this is an international ini-
tiative, the largest of its kind in the world, and now includes over 5,000 children. The study 
aims to identify genes that cause or increase the risk of childhood cancer occurrence. This 
can lead to screening or preventative treatments to reduce the risk of cancer and improved 
diagnosis and management of children with cancer. More broadly, identification of genes that 
cause cancer increases our understanding of how and why cancers occur. This is a long-term 
research program intended to run until at least 2020, and typically meant to find at least one 
new gene a year. 
THE IMPACT 
The potential repercussions of these fundamental findings could be critical in the fight against 
childhood cancers. However, the full, long-term implications of faulty genes can take many 
years to be fully understood, and will be the subject of ongoing long-term research. The 
development of specific drug therapies tailored to genetic defects will indeed take many 
years. However, the FACT project will make all the relevant information available so that 
drug companies and researchers in drug development can take it forward. In fact, the Insti-
tute of Cancer Research strongly values and favors close interaction between scientists and 
clinicians. This results in a rapid and efficient flow of findings from the laboratory into pilot 
clinical studies, and speeds up the delivery of scientific advances in diagnosis and treatment 
into real patient benefit.
IN THE FIELD
Identifying genes that cause childhood cancer
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RESEARCH EQUIPMENT  
As research advances and becomes more and more sophisticated, labs need to have access to the 
best cutting-edge technology in terms of machines and equipment. For example, DNA microarray 
technology uses robotic machines to arrange minuscule amounts of hundreds or thousands of 
gene sequences that enable scientists to study which genes are active in different cancer cells. 
Financing projects to improve equipment is absolutely vital if research is to evolve, and so is 
providing labs with access to this technology, which is often quite expensive.  
SPURRING TALENT
There is a very real need to help spur talents in basic research, especially in emerging countries 
where neither the infrastructure nor the educational system offer many opportunities to nurture 
young promising researchers. You could, for example, support initiatives that help young scientists 
to access top-notch training, either by developing local capacities or through scholarships, 
exchanges with excellence-centers or distance learning platforms. 
MAPPING UNDERFUNDED AREAS OF RESEARCH
The scope of basic cancer research is vast. In recent years, some topic areas have attracted growing 
attention from private and public funders, such as genomics, whilst others remain relatively 
underdeveloped.  One way to address this problem would be to support a global mapping of 
existing research projects, which would help to identify areas that are currently under-researched 
and underfunded. 
INCREASED TRANSPARENCY AND COOPERATION
Research is simultaneously competitive and collaborative. Although information sharing is vital 
if research is to advance, there is a great deal of fragmentation running across geographic and 
thematic borders. To help make the sector stronger, you may want to fund initiatives that help 
information flow, such as open-source databases, medical journals, and the standardization of 
certain research methods (thereby making results comparable). 
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Efforts to explore the basic mechanisms underlying cancer cover a wide range of 
activities, including basic research, which is typically undertaken by universities and 
financed by public funding or by private donors. It consists of long-term projects that 
will reap fruits only after decades, but that do constitute the necessary footing on which 
other, more applied, research is developed. Here are a few examples of concrete needs 
that you, as a private donor, may want to consider. 
UNRAVELLING COMPLEXITY

“The fight against cancer 
is both a personal  
and global one. 
One in which we all 
have a role to play.” 
Tuan Nguyen, 27, 
designer
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Targeted drug therapy (also known as molecularly targeted drugs) is a major theme of  
translational cancer research today: it holds the promise of being more selective, thus harming 
fewer normal cells, reducing side-effects and improving the patient’s quality of life.
In fact, targeted therapy blocks the growth of cancer cells by interfering with the specific 
targeted molecules needed for tumor growth and progression, rather than by simply interfering 
with rapidly dividing cells (e.g. with traditional chemotherapy). 
Targeted cancer therapies are being studied for use alone, in combination with other targeted 
therapies, and in combination with other cancer treatments, such as chemotherapy. In the 
United States alone, translational research has already produced over 40 molecularly targeted 
drugs that have been approved for human treatment. Translational oncology brings almost  
daily a new molecularly targeted drug to be tested clinically. Eventually, treatments may be 
individualized on the strength of the unique set of molecular targets produced by a patient’s 
tumor. 
Other applications of translational oncology include the search for a therapeutic or preventive 
vaccine against cancer (see ‘In the field’), for new and more effective biomarkers, for improved 
treatments and therapies etc.
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information and data Hypothesis andresearch design
Product development
The past decade has seen unprecedented interest in 
translational cancer research, also known as “trans-
lational oncology”. This area represents a critical 
one, since it bridges the gap and allows discove-
ries arising from basic research to be transformed 
into practical clinical applications that respond to 
patient needs. 
Indeed, as the wealth of knowledge and informa-
tion produced by fundamental researchers pours in, 
it has to be made “actionable” and transformed into 
concrete tools, treatments and procedures that will 
be able to save lives. 
To this end, translational cancer research explores 
ways of applying cutting-edge scientific discovery 
to new approaches to cancer prevention and treat-
ment. By the same token, it also aims to prevent 
basic researchers from losing sight of the pressing 
needs of cancer patients and reduce the time it takes 
for a promising research finding or concept to be 
tested, prior to being used on patients. 
“Translational oncology is a  
highway of information.  
It covers a whole gamut of  
activities—from basic sciences  
using mouse models to  
clinical trials with patients. It takes  
ideas and findings from the laboratory  
into the clinical setting and it reduces  
the time taken to find solutions  
to clinical questions.”   
George Coukos,











RICHARD SIMON,  CHIEF OF THE BIOMETRIC RESEARCH BRANCH IN THE DIVISION 
OF CANCER TREATMENT AND DIAGNOSIS OF THE UNITED STATES 
NATIONAL CANCER INSTITUTE.
You recently published a critical review on translational research in oncology.  
What are your criticisms? 
Progress in preventing or treating many types of cancer has been slow, and most metastatic solid  
tumors are still incurable. The public can be excused for asking when progress in basic research  
will be translated into greater patient benefit. Why is success always around the corner? Why do the 
breakthroughs in basic research so rarely translate to breakthroughs in treatment? Although there are 
many reasons for optimism in the future, in order to move forward effectively, it is important to look 
backward critically and identify key problems.
 
What is holding up progress?
There are roadblocks to progress. The main problem as I see it is that the pharmaceutical companies 
mostly develop drugs that are easy to develop. They don’t develop drugs against mutations that are 
commonly found in tumors but that no one knows how to “target”. Basic research has discovered those 
mutations, but no one is translating those findings into clinical benefit because no one knows how to 
do it. The basic research findings are not translatable without extensive new research of the type that is 
too high-risk for either academics applying for grants or for the pharmaceutical industry. And so it never 
happens.
Another roadblock, of course, is the complexity of trying to bring a new drug to the clinic. You have to 
overcome regulatory issues, human subject approvals, intellectual property issues, lack of funding, lack 
of patients, lack of training for physician-investigators, and a fragmented infrastructure for research. 
So you are pessimistic about the future of translational oncology? 
A basic research by individual investigators working alone and genetic sequencing work on tumors have 
led to great improvements in our knowledge of tumor development. I am optimistic that such progress in 
basic research will continue. But generally speaking, progress in translational research has been limited 
by an inadequate understanding of the process of tumor development. I believe that today overcoming 
roadblocks to translating basic research into clinical applications may require the creation of new  
organizations or the funding of teams focused specifically on key high-risk projects. And that may 
require a paradigm change.
“WHY DO THE BREAKTHROUGHS IN BASIC RESEARCH SO 
RARELY TRANSLATE TO BREAKTHROUGHS IN TREATMENT?”
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THE PROBLEM
For a long time, it was thought that the immune system did not recognize cancer cells as an 
enemy, as it does with viruses and bacteria, and hence triggers no immune reaction letting it 
grow uncontrollably. Studies have demonstrated that this might not be completely true, and that 
cancers are associated with specific substances (known as antigens) that trigger the response of 
the immune system. Over the past 10 years, there has been remarkable progress made and an 
accumulation of scientific evidence for the concept of cancer immunology, and how to make 
this knowledge useful for the development of a lifesaving vaccine. 
THE IDEA
After a decade of basic research, researchers at the Pasteur Institute in Paris have succee-
ded in stimulating immune system responses to antigens specifically associated with certain 
tumors, paving the way for the development of therapeutic cancer vaccines. One particular 
antigen – Tn – attracted their attention, being present in large numbers on the surface of 
adenocarcinomas such prostate, colon, breast and lung cancers. This discovery was further 
developed, and after years of translational work, the Institute’s researchers were able to deve-
lop a new type of compound (code-named MAG-Tn3) which triggers the rejection of the 
tumors by the immune system. A strongly positive stimulation of the immune system by 
this compound was demonstrated in mice, provoking a very strong antibody response which 
prevented tumor growth in 70% to 90% of cases, and the disappearance of the tumor in 80% 
of cases. The team then worked on preparing a candidate vaccine for tests on patients. This 
meant conducting a feasibility study for industrial production of the vaccine using a chemi-
cal synthesis procedure, the production of a clinical batch, and a toxicology study. Having 
successfully completed all these stages, the candidate vaccine is now ready to be approved 
by the authorities and to be clinically tested on humans.
THE IMPACT 
The Pasteur researchers are preparing their vaccine for submission to the French regula-
tory authorities with a view to testing it in human clinical trials, initially for its safety and 
for its ability to produce sufficiently strong immune responses. If the results of these trials 
are positive, the vaccine will be tested for anti-tumor efficacy in progressively larger-scale 
human trials on patients. There is great hope that the final results of this work will prove to 
be a significant breakthrough in the fight against adenocarcinomas, which account for the 
majority of cancer cases.
IN THE FIELD
From molecule to vaccine
4
IMPROVE TRAINING AND LEARNING OPPORTUNITIES 
One barrier to the translation of basic discoveries into solutions that benefit patients is the 
relative lack of multidisciplinary educational opportunities and the full-time work contract 
required by both research and clinical institutions that binds researchers and clinicians to their 
respective desks. This is why you may wish to support training initiatives, fellowships and/or 
exchanges that help break this dichotomy and give experts a “protected translational time” that 
could provide the necessary stimulus to produce life-saving outcomes for patients.
FOSTER COLLABORATION
Cooperation underpins translational cancer research: physicians must be able to mingle freely and 
frequently with researchers and vice versa. Although many donors may not think about it, supporting 
researchers by paying for their travel expenses, participation to seminars, or the organization of 
workshops and conferences that allow for sustained collaborative efforts and knowledge exchange, 
helps generate new solutions. Another initiative you could consider to increase collaboration would 
be to support the creation of an association focused specifically on translational research. 
ATTRACT TALENTED PEOPLE AND RAISE THE PROFILE
Translational research remains a relatively low-profile area for researchers, and the lack of funding 
keeps many talented researchers away from this field. You may want to address this by creating or 
supporting a competition or an award that would raise the profile of translational research projects 
in the cancer world and spur advances in this domain. 
HIGH RISK OPPORTUNITIES 
Neither funding agencies nor the pharmaceutical industry are prepared to run the risk of funding 
innovative research projects. Although relatively risky, some of these projects have enormous 
potential. So if you are a donor who is willing to take some risks, this is a perfect area for you. 
Research projects on targeted drug therapies, preventive cancer vaccines and more effective 
biomarkers are all promising areas that require additional funding from private donors.  
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DONOR’S CORNER
Whilst providing a key link between the lab and the patients, translational research 
has, until recently, been an underfunded and poorly recognized area. Although funding 
for basic research is typically covered by government funding, and clinical research is 
undertaken by the pharmaceutical industry, translational research easily falls between 
the cracks. This is especially true in times of economic hardship, when public funding 
is drying up and the pharmaceutical industry is increasingly adverse to the risks that 
innovative, but untested, solutions imply. Private donors and foundations can provide 
key funding in this area.
BRIDGING THE GAP BETWEEN THE LAB AND PATIENTS

“We used to die of cancer.  
Today, we live with it.  
And tomorrow,  
perhaps we’ll be cured of it.” 

































MAKING IT WORK IN PEOPLE
Clinical trials are one of the final stages of a long 
and painstaking cancer research process. 
Where as basic research seeks answers to ques-
tions about the disease and its underlying mecha-
nisms, clinical research seeks answers to ques-
tions relating to patients and how they respond to 
drugs and procedures aimed to prevent, detect or 
treat diseases. 
In cancer research, a clinical trial is designed to 
show how a certain preventive approach, a new 
diagnostic test, a promising drug or a new surgi-
cal procedure can affect the people receiving it. 
Although patients know that participating in these 
trials does not necessarily guarantee them a better 
chance of survival, it does represent an important 
contribution to the overall fight against the disease. 
As Wally Yocum, who was diagnosed with chronic 
lymphocytic leukemia in his mid-fifties, explains: 
“I’m also doing this so that maybe someday others 
won’t have to go through it. Maybe I can be part 
of a trial that leads to a cure, or at least to better 
treatment. The number of people you can help by 
doing something like this is infinite.” 
A LONG AND WINDING ROAD
It takes an average of 12 to 15 years from the 
time a discovery is made in basic research until 
it reaches your drugstore. This is partly due to 
rendering the discovery actionable (translational 
research- see Chapter 4), for example using that 
knowledge to produce a candidate drug, fine-tu-
ning the right catalysts and adjuvants and testing 
its safety and effectiveness on animals. Once a 
candidate is available and has received appro-
val from the competent national authorities, the 
long, and sometimes excruciatingly slow, journey 
through the many phases of clinical trials may 
commence (figure p. 52). 
These trials are conducted according to a progres-
sive step-by-step sequence, each with a distinct 
goal, as described below.
PHASE I: The first set of trials are conducted on 
approaches that appeared promising after exten-
sive laboratory research, animal testing, and the fi-
ling of an application with the competent national 
drug authorities. The purpose of this phase is to 
focus on determining the safety and side-effects, 
as well as the proper dosage of the drug. Only a 
small number of people (usually a couple of do-
zen) are accepted to take part in these studies, and 
they usually volunteer because other treatments 
are no longer effective. 
PHASE II: A slightly larger group of participants 
is involved to further investigate safety, dosages, 
and to get a preliminary idea as to whether the 
approach has a positive effect against the cancer.  
PHASE III: These trials, which usually involve 
hundreds or even thousands of volunteers, com-
pare the new approach with the best standard 
approach, and this is the final phase before the 
national drug authorities’ approval. Some people 
enrolling in this type of trial are randomly chosen 
to receive the new treatment, whilst others will 
be offered the standard treatment (control group). 
The purpose of this type of trial is to determine 
whether the new treatment is more beneficial than 
the standard therapy or indeed if it adds any bene-
fit at all.
If all these steps are successful, the approach can 
then be submitted to the country’s regulatory au-
thorities that make the final decision whether to 
allow the drug or procedure to be used on human 
subjects or not. The fourth and final step, once the 
drug or procedure is being used, involves surveil-
lance of the population to detect any side-effects 
that could justify withdrawal of the drug.
5
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VINCENT DIEBOLT,  HEAD OF THE FRENCH NATIONAL CENTRE  
FOR THE MANAGEMENT OF CLINICAL TRIALS  
ON HEALTH PRODUCTS.
Clinical trials on innovative drugs are sometimes criticized for not giving priority to the 
needs of the patients participating in these trials.  
First of all, a clinical trial must be carefully planned and based on a scientifically sound hypothesis.  
The possible risks to participating patients must also be carefully evaluated before starting a trial.  
And the researchers organizing the trial must ask themselves if the trial is likely to produce worthwhile 
information. Secondly, patients should be told that any new drug or procedure that is ready for a trial 
on human subjects will have already been tested in laboratory studies and on animals not only for its 
efficacy, but more importantly, for safety.
 
Some cancer patient associations complain that clinical trials often fail to keep patients 
properly informed about their role in the trial and the risks involved. What are your views 
on this?
This brings up the question of informed consent. Of course, the patient has to be informed. But  
how much information should be given? Should the consent form be so exhaustive as to be almost  
unintelligible? Or so concise as to be incomplete? It’s a real dilemma. And, of course, very often a 
cancer patient is in a fragile psychological or physical state and may not be able to fully understand the 
informed consent process. Should the investigator seek advice from a family member of the patient? 
My view is that as far as possible one should allow the patient, however ill, to make his or her own 
decisions.
What about patients who receive a placebo and not the actual drug, and don’t know which 
they are getting? 
A placebo should never be given to a patient if this procedure is likely to worsen the patient’s health. 
And the patient should always be informed from the outset that there is a 50% likelihood of being given 
a placebo and not the real drug, if that is how the trial is being set up.
The possibility of entering a clinical trial on a new drug is often proposed as a last resort 
to a patient in the terminal stages of cancer. Can such a patient really refuse to take this 
last chance?  
I hate to say this, but such a patient often has neither the time nor the option of refusing. I believe that at 
this stage of the disease, the patient should be told not so much about the risks, but about the chance, 
however slight, of surviving thanks to the new drug. The patient should be informed, though, that taking 







 “ONE SHOULD ALLOW THE PATIENT TO MAKE HIS OWN DECISIONS.”
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5
THE PROBLEM
In up to 40% of patients with so-called “non-small-cell lung cancer” (NSCLC), which is the 
most common type of lung cancer, the cancer cells carry on their surface an abnormal molecule 
called EGFR. This molecule makes the tumor grow and spread more quickly. The results of a 
clinical trial on a new drug that inhibits the action of the EGFR molecule were presented to the 
American Society of Clinical Oncology (ASCO) at its meeting in June 2012. The new drug is 
called ‘afatinib’.
THE IDEA
The clinical trial was conducted to determine the efficacy of afatinib in NSCLC patients 
with the abnormal EGFR molecule. A total of 345 patients participated in the trial. None had 
received any previous treatment. The patients were divided into two groups: one group was 
treated with standard intravenous chemotherapy, and the other with the afatinib tablet.
THE IMPACT 
After eight months, the tumors of the chemotherapy group had progressed twice as fast 
as those of the patients on afatinib, suggesting that the drug could indeed prolong survi-
val of these lung cancer patients by almost a year. The trial will continue for up to two 
years, by which time the total survival time gained thanks to afatinib will be known. The 
chief investigator of the trial, Professor James Hsin Yang of the National Taiwan Uni-
versity, told the ASCO meeting that the new drug not only appears to lengthen patients’ 
lives, but also reduces their symptoms, thus improving their quality of life. What’s more, 
since the drug is taken orally, patients do not need to attend hospital, as they do for weekly 
chemotherapy sessions. Boehringer Ingelheim, the manufacturer of the drug, has star-
ted recruiting patients for a new clinical trial comparing afatinib with the two other drugs 
on the market designed to inhibit the growth of EGFR-positive lung tumors.
IN THE FIELD
A life-prolonging drug against lung cancer
5
INFORMING AND PROMOTING TRIALS 
For a variety of reasons, few patients have the opportunity to participate in trials, and this has 
a range of unfortunate consequences. Some trials have to be abandoned because of a lack of 
patients, and others, such as those for relatively rare kinds of cancer, can never be conducted 
at all. Moreover, the elderly, a burgeoning group amongst those who will require treatment, are 
seriously underrepresented in clinical trials, as are minorities and, in some areas, women. You 
may decide to support advertising campaigns, social media platforms, or online databases and 
search engines to inform both more patients and doctors about the trials that are going on, their 
benefits and their drawbacks, to help increase and inform participation. 
TWEAKING THE FORMULA
Treatments that are safe and effective when used under certain conditions or in certain countries may 
not be so when used in other parts of the world. In fact, different doses or dose regimens may be required 
depending on a number of factors (climate, ethnicity, diet or other diseases). Plans are 
underway, for example, to test certain chemotherapeutic drugs in a number of developing countries on 
children with cancers, such as leukemia and Burkett’s lymphoma, that generally respond well to 
chemotherapy in the richer countries of the world, but that need to be slightly changed to best suit 
local conditions. Funding, however, is lacking for these sorts of trial, which hold relatively little 
commercial interest for the pharmaceutical companies. 
REINVENTING THE WHEEL
Once a treatment has been approved by the authorities and is on the market, phase four trials may 
be conducted to improve drug composition, its cost-effectiveness, or to see whether the same drug 
could be used for other cancers or uses. These trials, which can hold great promises and build 
on existing successes, are still relatively rare and seldom find funding within the pharmaceutical 
industry, so as a private donor, you may want to support the implementation of these trials.  
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Clinical research is primarily funded by pharmaceutical companies, which are 
usually the ones best placed to assess the potential of a finding or a discovery, 
and as such provide funding to the clinical trials needed to put it on the market. 
Despite this, private donors may want to explore this area to help overcome 
existing bottlenecks or to fund trials that hold great potential or are disregarded by 
the pharmaceutical industry. Here are a few ideas of clinical research areas that 
a private donor may want to consider:
MAKING IT WORK IN PEOPLE

“Basic research could lead to  
the discovery of particularly effective 
individualized therapy.”
Lucienne Bigler-Perrotin, 
57, Director of the Geneva  
Cancer League
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COMPLEMENTARY AND ALTERNATIVE MEDICINE
Complementary and alternative medicine (CAM) is the term for medical products and practices 
that are not part of standard medical care. Claims made by CAM treatment providers about 
their benefits appear promising, and studies are underway to determine the safety and  
usefulness of many cancer-related CAM practices.
Overview of CAM Approaches:
•  Alternative Medical Systems, such as acupuncture, Ayurveda, homeopathy and traditional 
Chinese medicine have evolved over time in different cultures and parts of the world for 
use in cancer and other conditions.
•  Mind-Body Methods, including meditation, hypnosis, and certain types of yoga practices, 
are based on the belief that the mind can affect the body’s response to cancer. These 
methods may help to reduce the side-effects caused by the treatment, and improve  
physical, emotional and spiritual well-being.
•  Nutritional Methods claim that special diets or supplements can be used in the treatment 
of people with cancer. Examples that may benefit cancer patients are macrobiotic diets 
and antioxidants.
•  Pharmacologic and Biologic Treatments involve the use of prescription drugs in a way not 
originally intended; vaccines, hormones, natural products (also called botanicals), and 
other biologic treatments used in the treatment of people with cancer. Herbal extracts and 
other herbs are also included.
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CURING AND IMPROVING CHANCES OF SURVIVAL
The classic treatment of a cancer patient uses a 
combination of chemotherapy, surgery and radia-
tion therapy. This medical weaponry is required to 
penetrate the formidable defenses of most cancers.
THE THREE PILLARS OF CANCER TREATMENT
SURGERY: Surgery remains the mainstay of 
cancer treatment, and alone it cures about half of 
solid tumors (such as breast and colorectal), which 
represent 95% of cancers. Despite advances in 
other treatment approaches, cancer experts believe 
that surgery will continue to play a fundamental 
role in cancer treatment. New technologies, such 
as robotic surgery or the use of tiny (laparoscopic) 
incisions to insert cameras and surgical instruments 
to perform image-guided operations, will no doubt 
make surgery even more effective, less invasive, 
and more precise.
RADIATION THERAPY: For over a century, 
since the discovery of X-rays in 1895, ionizing 
radiation has been used to treat cancer patients. 
Radiation therapy uses high-energy radiation to 
shrink tumors and kill cancer cells by damaging 
their DNA. X-rays, gamma rays and charged 
particles are types of radiation used for cancer 
treatment. The radiation may be delivered by a 
machine outside the body, or it may come from 
radioactive material placed inside the body near 
the cancer cells (internal radiation therapy, also 
called brachytherapy).
 
Radiotherapy is one of the least expensive cancer 
treatments, and one of the most effective in terms 
of cure and overall survival. It works best and can 
be curative on tumors that are small and localized. 
For larger tumors, radiation therapy is generally 
used after the tumor has been removed surgically, 
shrunk by chemotherapy, or rendered more vulne-
rable to radiation by certain radio-sensitizing 
drugs. On the other hand, for metastatic tumors 
that have spread to different parts of the body, 
radiation cannot be used. Radiation typically also 
“The big world of drugs provides 
us with remarkably few cures.  
When we look overall at  
solid tumors, the cure rate 
 with drugs is extremely low 
and in most cancer types 
it’s a big question to ask 
if we can cure anybody 
with these drugs.”   
Alexander Eggermont,
Director, Institut Gustave Roussy 
damages healthy tissues surrounding the tumor, 
leading to side-effects (see Donor’s corner p. 66).
CHEMOTHERAPY: First used in the 1950s, che-
motherapy uses drugs to destroy cancer cells by 
stopping or slowing their growth. Today, cancer 
clinicians have a choice of more than 100 different 
drugs they can pit against cancer. Generally, a 
combination of drugs acting in different ways is 
used simultaneously to overcome the resistance 
of cancer cells to individual drugs. Chemothe-
rapy works best on “young” tumors that have not 
yet built a tissue shield that prevents drugs from 
penetrating the tumor. Nonetheless, chemotherapy 
remains a costly procedure and the least effective 
in terms of cure and overall survival.
 
Moreover, the greatest inconvenience of chemo-
therapy is that the drugs target all fast-growing 
cells, regardless of whether they are cancerous or 
healthy. It therefore harms healthy cells that divide 
quickly, such as those that line your mouth and 
intestines or cause your hair to grow, causing phy-
sical and psychological pain. New types and com-
binations of chemotherapy drugs, including drugs 
that target the cancer cells more selectively, have 
slightly reduced the severity of side-effects and 
have increased the proportion of cures for some 
types of cancer, notably childhood leukemia and 
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6
BEYOND STANDARD TREATMENT
An area of clinical research that has become parti-
cularly dynamic in recent years is the assessment of 
treatment approaches that go beyond the traditional 
surgery-chemotherapy-radiation triad. Here are a 
few examples of approaches that are theoretically 
promising, but are still under study: 
TARGETED OR MOLECULAR THERAPIES 
(see Chapter 4) are delivered by drugs or other 
substances that block the growth and spread of can-
cer by interfering with specific molecules involved 
in tumor growth and progression.
GENE THERAPY introduces genes into a pa-
tient’s body that arrest the growth of tumors or pro-
duce substances, such as certain enzymes, that can 
make cancers more vulnerable to chemotherapy. 
TELOMERASE THERAPY is based on the fact 
that most cancer cells are immortal, thanks in large 
measure to a chemical substance called “telome-
rase”. Several drugs are being tested in human 
(clinical) trials for their ability to counter the effect 
of telomerase and make malignant cells die after a 
limited number of cell divisions.
PHOTODYNAMIC THERAPY uses light in 
combination with a drug that becomes active when 
exposed to light of a certain wavelength. Several 
photosensitive drugs are being tested for use in this 
therapy.
RADIOFREQUENCY WAVE TREATMENT 
uses radio waves to heat tiny particles of metals, 
such as gold or carbon, that have been implanted in 
the cancerous tissue. Tests on animals have proved 
promising, and clinical trials on human subjects 
may soon begin.
TUMOR TREATING FIELDS is a therapy that 
uses external electrodes to create an electric field 
in a part of the body where a tumor is located. The 
electric field disturbs the rapid division that cancer 
cells usually undergo. This therapy is in early clini-
cal trials for the treatment of certain cancers. Some 
trials have produced promising results.
HYPERTHERMIA (or thermal) therapy exposes 
body tissues to high temperatures in order to kill 
cancer cells. It is nearly always used with radiation 
therapy or chemotherapy. Many clinical trials are 
underway based on this approach and some have 
shown a significant reduction in tumor size when 
hyperthermia is combined with other treatments 
(see ‘In the field’).
HIGH-INTENSITY FOCUSED ULTRA-
SOUND THERAPY is a form of hyperthermia 
therapy that introduces ultrasound energy into the 
body. Since 2001, it has been used extensively in 
China and other South-East Asian countries. It was 
first used to treat prostate cancer, and has since 
been successfully used to destroy many types of 
solid tumors. In the West, the approach is still being 
investigated for its effectiveness.
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DON S. DIZON,  DIRECTOR OF MEDICAL ONCOLOGY, WOMEN AND INFANTS 
HOSPITAL, PROVIDENCE, RHODE ISLAND, USA.
You recently posted a description of a case of “autonomy” in a patient with cancer of the 
ovary on the American Society of Clinical Oncology website. Why autonomy, and what 
was so special about this case?  
I had just had a discussion with a colleague about how to improve the quality of life of a cancer patient 
while making sure the cancer was being treated. We got onto the subject of what is meant by the term 
“acceptable treatment toxicity” and who decides what is acceptable. And that reminded me of this patient. 
She was in her 50s and had a cancer of the ovary. She had had three courses of chemotherapy. From her 
treatment history, I saw that she had never been given PLD (pegylated liposomal doxorubicin), one of the 
most effective drugs against ovarian cancer. So I suggested to her that she should be put on this drug. 
But she refused point blank.
 
What was your reaction?
I just couldn’t believe it. I asked her how she could refuse a drug that would effectively fight her cancer. 
She said she knew about PLD and the skin reactions it could cause. She said she was afraid that these 
skin reactions would prevent her from wearing high-heeled shoes. She said to me: “Dr. Dizon, my cancer 
has deprived me of so many passions. I have very few left. One is my love of shoes, particularly  
high-heeled shoes. Believe me, my life will not be worth living if I cannot wear those shoes. No drug is 
worth giving them up.”
Did you insist? 
I was so surprised. I thought how foolish she was being. After all, I was offering a drug that could help 
stop the cancer in its tracks and prolong her life. And yet, instead of taking my advice, she rejected it; 
wouldn’t even consider it. And then it came to me that it was not for me to determine what toxicity is 
“acceptable.” I am not the one who must live with treatment and its impact on daily life. She has to look 
at herself every day, fight cancer, and fight to remain true to who she is despite the cancer.
And the lesson you draw from this encounter?   
Perhaps one of the hardest lessons for an oncologist is to acknowledge that despite the best evidence, 
we cannot dictate treatments. Cancer takes away so much from the person living with it. It forces our 
patients to change, to accommodate to it and its therapies. Because of this, I have a deep respect for 
the ability of our patients to choose. In our mission to provide comfort and hope, we must accept without 







 “CANCER TAKES AWAY SO MUCH FROM THE PERSON LIVING WITH IT”
65
CURING AND IMPROVING CHANCES OF SURVIVAL
THE PROBLEM
Breast cancer commonly calls for the surgical removal of the tumor. Depending on the stage 
of advancement and spread of the tumor, the operation can be mutilating. A Swedish team has 
pioneered a “minimally invasive” method that uses heat to kill cancer cells in small, early breast 
cancers.
THE IDEA
The method, called Preferential Radiofrequency Ablation (PRFA), aims to provide a more 
“patient-friendly” technique for the management of breast cancer. The technique, which can 
be performed in about an hour as an out-patient procedure, consists of placing a thin elec-
trode into the tumor. Ultrasound imaging allows the operator to position the electrode exactly 
in the center of the tumor. The electrode is then heated to 85º C for 10 minutes. This proce-
dure kills the cancer cells without harming the surrounding tissues.
THE IMPACT 
The PRFA technique has a high success rate. In a study of the technique on 31 patients with 
breast cancer who had been scheduled for partial removal of the breast, PRFA completely 
destroyed the tumor in 28 of the patients, as verified by analysis of biopsy tissue. Complica-
tions are rare. Unlike invasive surgery, PRFA leaves no scars and requires no patient recovery 
time. Researchers at Sweden’s Karolinska University are studying the use of PRFA in elderly 
women who, because of their age, are not candidates for surgery. To date, the technique has 





Surgery remains the most effective curative approach we have against cancer. The quality of 
the equipment, the standardization of surgery and the training of surgeons are the cheapest and 
most effective ways of improving the outcome in the treatment of solid tumors. Given the lack 
of resources of the public health system, private funding can make a real difference in this field. 
For example, you could help a hospital buy a cutting-edge surgery robot that can perform very 
precise operations, for example in brain or pediatric surgery.  
TRAINING RADIOTHERAPY PROFESSIONALS
The most important component of any radiotherapy treatment is highly trained personnel in a 
variety of interrelated disciplines ranging from radiation oncologists to radiotherapy technicians, 
medical physicists and maintenance engineers. Investment in equipment without concomitant 
investment in training is counterproductive and dangerous. Funding in this area is low (especially 
in poorer communities) and you may wish to consider supporting special training initiatives to help 
technicians deign approaches that are comprehensive, replicable, of high quality and safe.
MORE DRUG RESEARCH
In the big world of drugs, only very few provide a real cure for cancer. Testicular cancer, leukemia 
and lymphomas are amongst the only cancers that we can now cure in very large numbers, but 
for most solid cancers (such as lung and pancreas), curative drugs are still not available. In other 
cancers, however, such as melanoma, there is some very interesting progress underway, and this is 
now being applied to other cancers. As a donor, you should try to look for research areas that are 
not sufficiently supported by the pharmaceutical industry; for example, research focused on very 
rare, but possibly curable, cancers (like early childhood or heart cancers).
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Treatment forms the crux of the struggle against cancer, and is one of the areas 
where progress is most urgently needed. In each treatment domain, there are still 
improvements to be made that could have a clear impact on the quality and 
outcome of care. Although national health systems and pharmaceutical companies 
remain major players in this domain, there is a significant margin of action for private 
donors interested in helping the improvement and development of treatment. 
MAKING IT WORK IN PEOPLE

“Universities and research institutes 
are increasingly contributing  
to the development of new therapies. 
Thanks to them and to donations,  
most cancers will probably  
be treatable by 2030 or 2040.”
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For individuals with cancer, theirs is a daily 
struggle, which requires holistic support. The same 
is true for their loved ones, who fight by their side 
against the disease. Moreover, even once cancer is 
won, returning to “normal” life may be a challenge, 
making survivorship a mixed blessing. 
There are a number of self-reinforcing actions and 
support mechanisms that can help improve the qua-
lity of life of patients, and these should be provi-
ded during and after each individual’s fight against 
cancer. 
Cancer chemotherapy and radiation therapy will, 
almost without exception, damage some normal 
tissue and the immune system. For a long time, it 
has been known that radiation both enhances and 
halts cancer growth. Damaging the immune system 
in turn is known to promote the growth of some 
other kinds of cancer. We do not yet have really 
outstanding treatments for most cancers. Modern 
medicine in general, and cancer treatment in par-
ticular, is very imperfect. In the hope of curing 
or helping patients, the medical profession uses 
rather drastic treatments for devastating diseases 
they know will kill someone in a short time. Many 
oncologists do not provide families with enough 
information for them to understand how drastic 
these treatments are and how serious their adverse 
effects can be.
As explained by Gregory, who lost his wife and is 
now devoting his life to supporting the fight against 
cancer: “The quality of life must be considered as a 
major decision point in cancer care. That element, 
which has been lacking for so long in most clinics, 
hopefully will be brought to the forefront. It takes 
time for doctors to sit down with patients and truly 
explain the benefits and the risks of treatment. In an 
ideal world, patients would consider the benefits and 
the risks of each treatment and make an informed 
decision with the guidance of a wise doctor. But, 
busy doctors seldom spend much time discussing the 
benefits and the risks, and few patients ever question 
whether treatment may do more harm than good.” 
PALLIATIVE TREATMENT AND CARE
Palliative medicine is primarily aimed at attenua-
ting the symptoms of a disease. Contrary to popular 
belief, its use is not confined to patients in the ter-
minal stages of their disease, but is and should be 
used at any stage of the disease to ease the pain and 
the collateral effects of treatment. Moreover, in re-
cent years, its scope has expanded to include relief 
not only from physical pain, but also from suffering 
and distress in all areas of a patient’s life—mental, 
emotional, social, etc. 
Palliative treatment is also used in combina-
tion with curative treatment. Several palliative 
approaches and technologies, for example, have 
been developed to make chemotherapy safer and 
more tolerable: so-called “anti-emetic” drugs can 
reduce the nausea and vomiting associated with 
chemotherapy. Other drugs stimulate the produc-
tion in bone marrow of red and white blood cells 
to replace the blood cells destroyed by chemothe-
rapy, thus helping to prevent severe infections that 
were common during cancer treatment. However, 
other recently-developed drugs can reduce the risk 
of bone fractures caused by metastases of certain 
cancers of the bone. 
Relief of pain, however, which is the cause of se-
rious suffering in about 80% of cancer patients, is 
the principal function of palliative treatment and 
pain-killing (analgesic) drugs. These drugs come 
in three main categories, ranked by strength of 
action, from the weakest, such as aspirin and para-
cetamol, to the slightly stronger, such as codeine 
(mild opioid), and the strongest, such as morphine 
(strong opioid). 
LIFE AFTER CANCER
After an earthquake, there are victims and sur-
vivors, and there is no doubt about who is who. 
The victims are dead and the survivors are alive. 
7
72
PROVIDING HOLISTIC CARE AND SUPPORT
“If you can do nothing else for a cancer  
patient, at least ensure that he or she 
doesn’t die in pain.  
Someone in pain can’t interact  
with anyone else and is completely  
shut off from family and friends.  
The solution – morphine –  
is very cheap and has been 
 around for 200 years.  
And it could be readily available.  
In some countries, however,  
there are regulatory barriers  
that prevent patients from being  
administered morphine.  
And there are also cultural barriers  
that must be pulled down.”   
Julie Torode, 
Deputy CEO, Union for International Cancer Control
When it comes to cancer though, things are not so 
clear-cut. A person diagnosed with cancer and who 
has been successfully treated is always aware that 
however successful the treatment was, he or she 
can never be sure that the cancer will not return 
or that a new cancer may not arise. The sword of 
Damocles has lifted somewhat, but is still there, 
and for an ex-cancer patient, this can be a source of 
permanent anxiety.
Today, over two-thirds of adults diagnosed with 
cancer in the developed world are expected to live 
at least five years after the cancer is discovered 
(these figures rise to 90% for cancers of the cervix, 
breast, prostate and colorectum). Progress in detec-
ting and treating cancers is producing a growing 
population of survivors and has already given rise 
to a new discipline: survivorship.
 
This discipline deals with the problems faced by 
survivors—and also their families, friends and 
caregivers—and the efforts needed to cope with a 
series of challenges. In fact, survivors and their lo-
ved ones often face physical, emotional, social and 
financial difficulties. They may also face problems 
of reintegration into society and of access to the 
entitlements, such as insurance and healthcare, that 
society provides. This is particularly true of already 
disadvantaged communities, such as poorer com-
munities or developing countries. 
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THE PROBLEM
Every year, more than 3.3 million people die in pain without access to adequate pain relief treat-
ment. Morphine is safe, inexpensive and easy to administer in resource-constrained settings. 
However, four out of five patients worldwide, most of whom are in developing countries, can-
not access pain relief because of a number of factors, including legal restrictions, weak health 
systems, poorly-functioning markets, and misconceptions about drug misuse and addiction. 
This is especially true in Africa, where the administration of morphine is very strictly regulated 
and rarely used: in Nigeria, for example, only a couple hundred patients receive palliative care 
and some 170,000 die every year without pain relief.
THE IDEA
Treat the Pain is a joint program of the Union for International Cancer Control (UICC) and 
the American Cancer Society (ACS) to make effective pain control measures universally 
available to cancer patients by 2020. This objective can only be achieved by working along-
side governments and civil society to overcome the obstacles that still prevent access to pain 
relief. This means raising awareness of this issue, changing legislation, ensuring appropriate 
supply and distribution, and training healthcare professionals to administer these drugs ap-
propriately. The Treat the Pain program is now being developed in several African countries, 
including Uganda and Nigeria.
THE IMPACT 
The approach was initially tested in Uganda, where it met with very encouraging results, and 
succeeded in lowering the price of morphine by 50% and making it accessible for free to all 
patients. In Nigeria, the second targeted country, the program aims to increase the number of 
patients receiving pain relief from the current count of 270 in 2010 to 100,000 by 2014. An 
agreement has already been signed with the Nigerian Ministry of Health to hire one full-time 
staff member to implement the project. The first real step in this direction was the govern-
ment’s purchase of 26 kilos of morphine – the morphine acquired since 2007 amounted to 
barely one kilo. 
IN THE FIELD
Providing access to painkillers in Nigeria
“This initiative will provide technical support to assist with the procurement of 
morphine, its distribution, and the scale-up of pain treatment services. We are 
hopeful that this important step forward by Nigeria, which is home to one in 
five Africans, signals the coming of a new era in government responses to the 
crisis of untreated pain”   
Meg O’Brian
Director of Treat the Pain
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MEDICAL SUPPORT AND COUNSELING 
Cancer survivors are at greater risk of cancer recurrence and of developing secondary cancers 
due to the effects of treatment, unhealthy behaviors, and other risk factors that contributed to the 
initial cancer. There are a lot of opportunities for you to support this problem area; for example, 
you could support projects, such as counseling services or mobile phone applications to help 
survivors keep to a schedule of follow-up visits and screening tests, inform them as to possible 
delayed effects of treatment, and help them identify early signs and symptoms. 
PSYCHOLOGICAL CARE
Helping patients and survivors to cope with their difficulties calls for counseling and strategies to 
improve the quality of their lives and psychological state. Each person, however, reacts differently 
to cancer: while some are overwhelmed and fall into a depressive or destructive pattern, others 
describe the process of fighting cancer as a life-changing experience and an opportunity to become 
“a better person” or to engage in constructive, positive and challenging endeavors. If this is an area 
that appeals to you, there is a big need for funding projects at a community and grassroots levels, 
which are key to helping patients deal with their disease as best they can. For example, you could 
support workshops or retreats, or an expedition to climb a mountain, a yoga workshop, etc.
FINANCIAL SUPPORT
Many patients coming from rural or disadvantaged backgrounds face a number of problems when 
they learn they have cancer. Even when treatment is covered by their insurance, they need to face 
a number of financial and logistical difficulties. By supporting or setting up solidarity funds, for 
example, you can support patients by providing gas vouchers or train tickets so that they can get to 
treatment, help them pay for palliative medicines, supply free or low-cost wigs, or offer babysitting 
support for single mothers.
SUPPORT TO FAMILIES AND LOVED ONES
One of the often overlooked victims of cancer is the patient’s family, which struggles against the 
disease alongside their loved one, and all too often have to deal with pain and loss. There is a 
lack of funding in this area, and you may consider supporting programs targeted at the families 
of patients, such as self-help groups to help them cope with the news or seminars to learn more 
about the disease and treatment opportunities, or counseling sessions to prepare them for the worst. 
Many of these initiatives already exist, but they must be scaled up and replicated around the world.
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Helping cancer patients and survivors, as well as their families, to cope with their 
difficulties and improve their quality of life is a crucial aspect of the fight against cancer, 
although it is often underfunded by the public sector and ignored by the industry. It is 
therefore a perfect area for private donors to explore, and bring ideas and resources 
to. Here are some of the many actions you could support to make a real difference to 
the lives of many.
PROVIDING HOLISTIC CARE AND SUPPORT

“To reduce the risk  
of developing cancer,  
we must understand  
what triggers the disease.  
Only research will  
help us do that.”
















Cancer is perhaps the most widely discussed disease today. We hear about it on television, 
read about it in the newspaper, participate in walks to raise money, and give donations from 
our hearts. It has touched the lives of almost everyone, whether directly or through a loved 
one, colleague or friend. So, it is surprising to find that in our information-saturated society, 
there are still many myths and misconceptions that abound. 
Surveys conducted both in the United States and in England show that many people have a 
very limited knowledge of what cancer is, how it can be prevented, and how it can be fought. 
Amongst some popular misconceptions that still exist today is the belief that cancer is  
contagious, incurable and unpreventable. There is also still a lot of misinformation as to what 
causes cancer, what the real incidence of certain factors is, and what treatments are actually 
proven to be effective. 
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Unlike the previous chapters, which dealt with 
specific activities being carried out in the struggle 
against cancer, this chapter deals with issues that 
are cross-cutting.
THE NEXT GENERATION OF ONCOLOGISTS
One critical need resulting from the massive up-
surge in cancer cases predicted over the coming 
years is the need for trained health professionals in 
all aspects of cancer research and clinical care. For 
a disease that covers such a wide range of human 
suffering—physical, mental, social, professional, 
and so on—the training of healthcare professionals 
will have to cover a correspondingly-wide range 
of disciplines. A further problem for developing 
countries is the substantial number of trained pro-
fessionals who migrate to richer countries that offer 
better financial and career incentives. 
SOME ARE MORE EQUAL THAN OTHERS
As the age-old dictum says, “we are all equal in 
the face of death”. But when it comes to cancer, as 
with many other diseases, it is the poorest who bear 
the greatest burden. More than two-thirds of cancer 
deaths worldwide occur in developing countries, 
which are increasingly experiencing the risk factors 
already afflicting developed countries (an aging po-
pulation, rapid urbanization and adoption of unheal-
thy lifestyles). However, developing countries are 
still lagging behind in terms of health services 
(screening, diagnosis, treatment, palliative care and 
support). If these countries had access to the exis-
ting technologies that benefit patients in developed 
countries, the burden of cancer would be hugely 
reduced. It’s important to note that inequalities are 
not only across national borders and developed/
developing divides: at national level, it is clear that 
a disproportionate rate of victims come from disad-
vantaged backgrounds and minority groups. 
KNOWING IS PREVENTING
Perhaps the greatest barrier to winning the fight 
against cancer is that even today, this disease is still 
a taboo subject for many, often creating an aura of 
fear and resignation. In many parts of the world, 
particularly in the less developed countries, cancer 
is an unmentionable subject. Fighting a “hidden as-
sassin” is an almost impossible task, and more needs 
to be done to bring this disease out in the light of 
day. Efforts to raise awareness and learn more about 
cancer play a central role in the fight against this di-
sease. The effectiveness of these efforts stems from 
the scientific knowledge that has accumulated over 
the past half-century about what raises the risks of 
cancer, and how this disease can be fought. 
“The first big step towards cancer  
prevention and control  
worldwide is to understand  
the magnitude and nature  
of the cancer burden”   
IARC 2008
In developed countries, much is being done on this 
front, and thanks to mass campaigns and the relati-
vely recent cultural acceptance of cancer as a disease 
that one can talk openly about, knowledge about can-
cer has, to a large extent, taken root, although much 
more must still be done (See Spotlight: Myths and 
Misconceptions). In developing countries, several 
barriers hamper efforts to raise awareness of cancer. 
Firstly, concern over cancer tends to be diluted in 
impoverished populations already burdened by an 
impressive roster of illnesses and other health-threa-
tening factors. Secondly, cancer is still a taboo sub-
ject in many places. And another barrier is the lack 
of adequate resources in terms of trained personnel 
and technologies to implement the logical follow-
up to awareness campaigns, namely, mass screening 
and effective therapy. 
COMING TOGETHER
Today, there are so many players on the cancer 
stage, doing so many different things, in so many 
different ways, that one can only be amazed that, 
in the absence of an overall coordinating entity, 
real progress is being made in the various areas 
of cancer activity. In the UK alone, there are an 
estimated 600 charities involved in cancer work. 
Anyone wishing to find out who is doing what and 
where faces a number of practical difficulties. Fur-
thermore, this multiplication of actors makes com-
munication and collaboration difficult, and often 
results in an inefficient duplication of efforts. 
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The Program of Action for Cancer Therapy (PACT) was set up by the International Atomic 
Energy Agency (IAEA) in 2004 to build on the Agency’s experience in radiation medicine and 
technology, and enable developing countries to introduce, expand and/or improve their cancer 
care capacity by integrating radiotherapy into a comprehensive cancer control program. 
The International Agency for Research on Cancer (IARC) is an inter-governmental agency 
based in Lyon, and is an extension of the UN World Health Organization. Its role is to conduct and 
coordinate research into the causes of cancer. It also conducts epidemiological studies into the 
occurrence of cancer worldwide. It maintains a series of monographs on the carcinogenic risks to 
humans posed by a variety of agents, mixtures and exposures.
The Union for International Cancer Control (UICC) is a membership non-governmental orga-
nization  based in Geneva, and is dedicated to the global control of cancer. The UICC unites more 
than 400 member organizations in over 120 countries in the global fight against cancer, and 
strives to coordinate global initiatives and change policies at the international and national level.
The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH), which 
is one of 11 operative agencies of the US Department of Health and Human Services. The NCI 
coordinates the US National Cancer Program and conducts and supports research, training, 
health information dissemination, and other activities related to the causes, prevention, diagnosis 
and treatment of cancer; the supportive care of cancer patients and their families; and cancer 
survivorship.
Cancer Research UK is a cancer research and awareness charity in the United Kingdom. As 
the world’s largest independent cancer research charity, it conducts research into the prevention, 
diagnosis and treatment of the disease. Research activities are carried out in institutes, univer-
sities and hospitals across the UK, both by the charity’s own employees and by its grant-funded 
researchers. It also provides information about cancer, and runs campaigns aimed at raising 
awareness of the disease and influencing public policy.
 
The German Cancer Research Center (known as the Deutsches Krebsforschungszentrum or 
DKFZ in German), is a national cancer research center based in Heidelberg. It is a member of the 
Helmholtz Association of German Research Centers, the largest scientific organization in Ger-
many, and carries out research into understanding the mechanisms of cancer development and 
investigates cancer risk factors.
The Institut national du cancer (INCa) is a French public interest group set up to coordinate 
scientific research and the fight against cancer. It brings together key players in the fight against 
cancer (state hospital associations, health insurers, cancer centers and the national cancer 
league), and funds cancer research projects at national level. One of the missions of INCa is 
the development of organized screening, to ensure that patients have equal access to care, to 
promote prevention, to act in the field of professional training, and to improve care and commu-
nication to patients and their families (in conjunction with the High Authority of Health and the 
Ministry of Health).
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THE PROBLEM
According to the World Health Organization, breast cancer is the most common cause of death 
among women in both developed and developing countries, claiming the lives of 600,000 glo-
bally. In Germany, breast cancer is the most common cause of death for women aged between 
40 and 44, and every year, some 60,000 new cases are diagnosed. Early detection and treatment 
significantly increase the chances of survival. However, the standard method used – mammo-
gram screening – is only offered to women aged 50 to 69, even though around 20% of breast 
cancer is detected in women under the age of 50. For these women, the only available screening 
method is palpation performed by their gynecologist as part of their routine check-up (usually 
once a year), but for which there is no standardized or evaluated method.
THE IDEA
Discovering Hands is an innovative program launched in Germany in 2006 that trains vi-
sually impaired women to detect early signs of breast cancer. After a two-year testing phase, 
the program is now in the process of being scaled up and expanded, both domestically and 
overseas. Its unique approach involves educating visually impaired women to enhance their 
already superior sensory skills to more accurately identify areas of inception and detect smal-
ler lumps. 
During a 9-month training program in disability centers, these women learn how to use stan-
dardized diagnostic methods for examining female breasts, as well as psychology, commu-
nications and administrative skills. They are either directly employed by resident doctors or 
hospitals, or work for different practices and/or hospitals on a freelance basis. The examina-
tion is either paid for by health insurance (to date, Discovering Hands has agreements with 
four companies in Germany) or by the patients themselves.
THE IMPACT 
Today, around 20 blind women are part of the Discovering Hands network, working in 17 
gynecology practices and hospitals throughout Germany. More than 8,000 examinations have 
been carried out to date. Preliminary qualitative results show that Discovering Hands exami-
ners have an approximately 50% better rate of overall detection than doctors, and an impro-
vement of approximately 30% when it comes to smaller tissue alterations in the breast. These 
results have generated interest from health services throughout Europe. Over and above the 
health benefits involved, Discovering Hands also has a further function in influencing per-
ceptions of disability. By using the extraordinary sensory capabilities of visually impaired 
women, a perceived “disability” is transformed into a capability, thus creating a new field of 
meaningful employment. 
IN THE FIELD
Training visually impaired women  
to detect breast cancer
8
TRAINING THE NEXT GENERATION
Forecasts suggest that the need for training cancer experts (researchers, medical 
staff, technicians and social workers) will be great. What’s more donors will have to boost their 
support in this area over the coming years. You could decide to help in this area by funding 
dedicated courses, chairs, fellowships, distance learning, etc. This may mean supporting courses 
for radiotherapy technicians in Cambodia, a Chair in translational research in France, or a north-
south exchange of surgeons between Latin American hospitals and North American ones. 
IMPROVING ACCESS
Guaranteeing universal access to good screening, detection, treatment and support is a pivotal 
challenge, not only in the fight against cancer, but the fight against many other diseases. In fact, 
technologies and drugs that are safe, effective and easily accessible in certain socio-economic 
contexts may not be so in poorer settings or peripheral locations. As a donor, you might wish to 
consider helping to bring new drugs or radiotherapy machinery to the rural regions of your own 
country, or create medical surgery facilities in developing settings. In other cases, such as palliative 
care (see page 71), for example, providing access may also mean supporting advocacy to bringing 
down the social, moral and legal barriers that prevent millions from having access to pain-relief 
treatments.
CANCER REGISTRIES
Much of our lack of information on the real impact of cancer is due to a shocking deficiency of 
cancer registries: less than 20% of the world’s population is covered by cancer registration (less 
than 9% in Africa as a whole). Without cancer registries, governments remain ignorant of the 
magnitude of the cancer burden, do not acknowledge the priority that this issue represents, and 
cannot justify mounting anti-cancer efforts. Registries also help researchers to understand patterns 
in cancer development, for example, incidence differences along ethnic lines, nutritional habits 
or environmental factors. These data can also be used to guide future prevention efforts, monitor 
changes in disease patterns, and tailor early detection and primary prevention strategies.
 
INCREASING COLLABORATION
Supporting conferences, partnerships and summits that help decrease the fragmentation of the 
cancer sector and increase collaboration are a key area of intervention for private donors today. 
Some of the main cancer stakeholders are coming together in membership umbrella associations, 
or are forming alliances. But a great deal more can still be done in this area to ensure that the whole 
is greater than the sum of its parts.
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Cross-cutting issues, like the ones presented in this chapter, are also often the ones 
that receive the least support from governments, and usually none at all from the pri-
vate sector. But they also require innovative, bold and out-of-the-box thinking, which is 
why they make the perfect ground for philanthropic engagement. 




You have come to the end of your guided tour of the fight against cancer. Perhaps now 
you feel more comfortable beginning your own voyage as an active explorer.
We hope that your journey through these pages has shed light on possible areas of 
need and of promise where you might wish to add your support.
There is little doubt that we have come to a pivotal moment in the struggle against cancer. 
Already, recent research breakthroughs are producing new diagnostic and therapeutic 
approaches and new drugs that are beginning to reduce the number of cancer cases 
and deaths. There is still a long way to go, but your participation in the fight against 
cancer could shorten the time to victory.
After turning the last page of this guide, you may have more questions, more doubts, 
more ideas that you would like to discuss. We are here to listen to you and help you 
decide if, where and how you might want to engage in what could be a turning point in 
the struggle to defeat cancer.
May we wish you success and fulfillment in your new journey.
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